Quick Answer
HCW Biologics Inc. reported Total Revenue of $4.10 million for fiscal year 2020.
HCW Biologics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | $4.10M |
| Net Income | -$7.96M +73.5% |
-$30.02M -20.1% |
-$24.99M -67.7% |
-$14.90M -15.8% |
-$12.86M -121.7% |
-$5.80M |
| Diluted EPS | -$10.63 +65.7% |
-$30.96 -4322.9% |
-$0.70 -66.7% |
-$0.42 +39.1% |
-$0.69 | — |
| Total Assets | $24.52M -18.9% |
$30.24M +6.0% |
$28.51M -39.1% |
$46.81M -12.5% |
$53.51M +247.5% |
$15.40M |
| Cash and Equivalents | $1.95M -58.2% |
$4.67M +30.0% |
$3.60M -83.9% |
$22.33M +90.3% |
$11.73M +38.7% |
$8.46M +15.0% |
| Long-Term Debt | $0.00 -100.0% |
$7.38M +17.0% |
$6.30M -1.6% |
$6.41M | $0.00 | — |
| Stockholders Equity | $2.76M +140.8% |
-$6.77M -150.3% |
$13.46M -64.0% |
$37.43M -26.9% |
$51.19M +406.2% |
-$16.72M -72.8% |
| R&D Expense | $5.44M -14.8% |
$6.39M -16.8% |
$7.68M -17.8% |
$9.34M +14.2% |
$8.17M +12.7% |
$7.26M |
| Operating Income | -$13.16M +55.3% |
-$29.46M -14.5% |
-$25.72M -70.6% |
-$15.08M -12.8% |
-$13.37M -129.5% |
-$5.82M |
| Gross Profit | $10.8K -98.9% |
$959.4K +71.2% |
$560.4K -78.3% |
$2.59M | $0.00 | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$4.55M | -16.7% | -136.3% |
| Diluted EPS | September 30, 2025 | -$2.02 | +51.1% | +70.3% |
| Total Assets | September 30, 2025 | $25.45M | -4.2% | -12.0% |
| Cash and Equivalents | September 30, 2025 | $1.10M | +9.9% | -55.0% |
| Long-Term Debt | September 30, 2025 | $0.00 | -100.0% | -100.0% |
| Stockholders Equity | September 30, 2025 | -$2.11M | +78.9% | -3954.5% |
| R&D Expense | September 30, 2025 | $1.40M | +18.3% | +14.5% |
| Operating Income | September 30, 2025 | -$3.29M | +10.7% | +5.0% |
| Gross Profit | September 30, 2025 | $3.1K | -96.3% | +138.2% |
- HCW Biologics Inc. reported Total Revenue of $4.10 million for fiscal year 2020.
- HCW Biologics Inc. reported Net Income of -$7.96 million for fiscal year 2025.
- HCW Biologics Inc. showed an increase of +73.5% in Net Income compared to the prior fiscal year.
- HCW Biologics Inc. reported Diluted EPS of $10.63 per share (loss) for fiscal year 2025.
- HCW Biologics Inc. showed an increase of +65.7% in Diluted EPS compared to the prior fiscal year.
- HCW Biologics Inc. reported Total Assets of $24.52 million for fiscal year 2025.
- HCW Biologics Inc. showed a decrease of -18.9% in Total Assets compared to the prior fiscal year.
- HCW Biologics Inc. reported Cash and Equivalents of $1.95 million for fiscal year 2025.
- HCW Biologics Inc. showed a decrease of -58.2% in Cash and Equivalents compared to the prior fiscal year.
- HCW Biologics Inc. reported Long-Term Debt of $0.00 for fiscal year 2025.
- HCW Biologics Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- HCW Biologics Inc. reported Stockholders Equity of $2.76 million for fiscal year 2025.
- HCW Biologics Inc. showed an increase of +140.8% in Stockholders Equity compared to the prior fiscal year.
- HCW Biologics Inc. reported R&D Expense of $5.44 million for fiscal year 2025.
- HCW Biologics Inc. showed a decrease of -14.8% in R&D Expense compared to the prior fiscal year.
- HCW Biologics Inc. reported Operating Income of -$13.16 million for fiscal year 2025.
- HCW Biologics Inc. showed an increase of +55.3% in Operating Income compared to the prior fiscal year.
- HCW Biologics Inc. reported Gross Profit of $10.8 thousand for fiscal year 2025.
- HCW Biologics Inc. showed a decrease of -98.9% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: